PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies
Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment expected in the third quarter of 2022
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies
Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment expected in the third quarter of 2022
Read more at globenewswire.com